SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Conflicting reports around Nvidia's 18A chip engagement are central to Intel's trending discussion, with many dismissing negative news as FUD and a "hit piece." The community expresses strong conviction in Intel's foundry turnaround, buoyed by US antitrust clearance for Nvidia's substantial investment and a significant partnership with the Department of Energy for AI scientific discovery. This optimism prevails despite perceived market manipulation and frustration over recent price action.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

OMER is trending on high anticipation for an imminent FDA approval decision for its drug Narsoplimab, targeting a deadly disease with no approved treatments. The community is buzzing with speculation around a potential "Christmas miracle" approval, fueled by the company's recent strategic partnership with Novo Nordisk and strong clinical data, anticipating a significant short squeeze and a re-rating of the stock's value despite past regulatory hurdles.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful launch of its BlueBird-6 satellite, a key milestone toward direct-to-device cellular broadband for standard smartphones. The community is buzzing with excitement over this validation of their next-generation technology, anticipating long-term bullish momentum as the company progresses toward commercial scalability. While many celebrate, some investors are also discussing potential short-term profit-taking given the recent run-up and holiday trading conditions.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as it prepares for inclusion in the S&P MidCap 400 index, a development expected to enhance its institutional visibility and liquidity. The community is actively discussing the potential for increased buying pressure from index funds and sees this as a significant validation. Many are also comparing UiPath to other rapidly growing AI stocks, recognizing its leadership in the Agentic AI and automation space.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending amidst intense shareholder frustration over leadership's perceived inaction on securing a major partnership for its differentiated non-mRNA vaccine assets, particularly following a competitor's recent acquisition at a substantial premium. The community is buzzing with speculation that an anticipated 'black box' warning for mRNA vaccines could significantly re-evaluate Novavax's market position, alongside ongoing pressure for a strategic buyout from activist investors.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending significantly due to an agreement for its acquisition by Sanofi through a cash buyout offer. This news is driving widespread community discussion, with many long-term investors expressing both relief and some frustration over the valuation after years of minimal stock appreciation, as Sanofi aims to enhance its adult immunization portfolio with Dynavax's vaccine assets and adjuvant technology.

Starfighters Space Inc

Starfighters Space Inc. ($FJET), a recent IPO in the aerospace sector, is experiencing extreme volatility, rocketing higher after its debut and subsequently plummeting. The community is sharply divided, with bulls anticipating a massive short squeeze and further "Mach 2" ascent due to its low float, while bears label it an overvalued "pump and dump" with questionable fundamentals and high dilution risk. This has created a highly speculative trading environment, with many discussing its potential as a meme stock versus a rapid decline.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amid starkly divided community sentiment, with many holders expressing frustration over current price levels and labeling it a "scam" or "dead" project. However, a passionate segment of the community remains highly confident, viewing this period as a key accumulation opportunity and anticipating a significant rally. This intense polarization and active debate around its future are driving conversations.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

AVNT is a trending crypto asset, heavily discussed for its recent listing on Robinhood and its role as a decentralized perpetual exchange built on Coinbase's #base app, targeting the Real-World Asset (RWA) sector. The community is actively debating its potential to outperform competitors like $ASTER and $HYPE, though sentiment is split between bullish optimism for upcoming developments and strong skepticism from those concerned about recent price volatility and perceived issues with token unlocks and buybacks.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X is experiencing heightened interest as market commentary highlights its advanced quantum sensing and timing solutions for national security applications. The community is actively discussing Infleqtion's (the merger target) commercially viable technology and strategic partnerships, positioning it favorably against other quantum sector peers. Many anticipate a significant re-rating and institutional investment once the impending merger is completed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of "Moderate Buy" by Analysts

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering...

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells $500,714.88 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 12,048 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was sold...

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Director Barry Quart Sells 20,129 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) Director Barry Quart sold 20,129 shares of the business's stock in a transaction that occurred on Monday, December 15th. The...

Braidwell LP Sells 860,329 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Braidwell LP lessened its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 43.8% during the second quarter, according to the company in its most recent...

Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CFO Sells 42,841 Shares of Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 42,841 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold...

Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Walleye Capital LLC

Walleye Capital LLC increased its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 39.1% in the 2nd quarter, according to its most recent 13F filing with the SEC...

Wedbush Reiterates Outperform Rating for Kiniksa Pharmaceuticals International (NASDAQ:KNSA)

Wedbush reissued an "outperform" rating and issued a $48.00 price target on shares of Kiniksa Pharmaceuticals International in a report on Tuesday...

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are covering the...

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 12-Month High - Time to Buy?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High - Time to Buy...

200,574 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Purchased by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. bought a new position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the second quarter, according to its most recent 13F filing...

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

KNSA
Kiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KNSA News

KNSAKiniksa Pharmaceuticals Ltd - Ordinary Shares - Class A